Heiko Methe

Heiko Methe

Auto-generated profile, based on publicly available information

Heiko Methe

Department of Cardiology, University Hospital Grosshadern, Ludwig-Maximilians University, Munich, Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2005 in Circulation
Verified
Journal Article
Closed access
PDF file
HMHeiko Methe
Heiko Methe
JKJong-Oh Kim
Jong-Oh Kim
SKSieglinde Kofler
Sieglinde Kofler
MWMichael Weis
Michael Weis
MNMichael Nabauer
Michael Nabauer
JKJoerg Koglin
Joerg Koglin
Background— Atherosclerosis is an inflammatory disease in which monocytes and macrophages have been suggested to play an essential role. The underlying signaling mechanisms are unknown thus far. We hypothesized that the human isoform of Toll-like receptor (hTLR)-4 is involved in monocyte activation of patients with accelerated forms of atherosclerosis. Methods and Results— Expression of hTLR4 on circulating monocytes from 30 controls, 20 patients with stable angina (SA), 40 patients with unstable angina (UA), and 28 patients with acute myocardial infarction (AMI) was compared with the use of flow-cytometry and reverse transcription–polymerase chain reaction. Regulation of interleukin (IL)-12 and B7-1 as downstream events of TLR4 activation was analyzed after lipopolysaccharide stimulation of monocytes. TLR4-transfected Chinese hamster ovary (CHO) cells were used to identify potential hTLR4 ligands in the serum of patients with UA or AMI. Circulating hTLR4 + /CD14 + monocytes were ≈2.5-fold increased above controls and patients with SA in the UA and AMI groups ( P <0.0001). This was paralleled by enhanced transcript levels of TLR4 and Myd88 in patients with UA and AMI ( P <0.0001) and increased expression of IL-12 (UA 35.5±7.8, AMI 31.8±7.7 versus SA 2.2±0.5, controls 2.1±0.3 pg/mL; P <0.0002) and B7-1 (UA 27.3±14.4, AMI 22.6±11.1 versus SA 3.4±2.5, controls 2.4±2.3%; P <0.0001). Compared with serum from patients with UA and AMI, challenging TLR4-transfected CHO cells with serum from SA patients yielded only a weak response ( P <0.0001). Coincubation with anti–heat shock protein 60 inhibited CHO cell activation. Conclusions— UA and AMI are associated with enhanced expression and signaling events downstream of hTLR4 in circulating monocytes. These observations suggest hTLR4 activation as a signaling mechanism in immune-mediated progression of atherosclerosis.

1 June 2005 in JACC
Verified
Journal Article
Closed access
HMHeiko Methe
Heiko Methe
SBStefan Brunner
Stefan Brunner
DWDaniela Wiegand
Daniela Wiegand
MNMichael Nabauer
Michael Nabauer
JKJoerg Koglin
Joerg Koglin
Elazer R. EdelmanElazer R. Edelman
Elazer R. Edelman

1 July 2005 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
HMHeiko Methe
Heiko Methe
JKJong-Oh Kim
Jong-Oh Kim
SKSieglinde Kofler
Sieglinde Kofler
MNMichael Nabauer
Michael Nabauer
MWMichael Weis
Michael Weis
Objective— Anti-inflammatory effects of statins contribute to their clinical benefit. Molecular mechanisms underlying these effects have not been well explored. Because statins attenuate lipopolysaccharide (LPS) responsiveness, we hypothesized that part of the pleiotropic effects are mediated through innate immunity. Methods and Results— Toll-like receptor (TLR) 4 expression and downstream signaling in CD14 + monocytes after incubation with simvastatin and atorvastatin were quantified via flow-cytometry, quantitative RT-PCR, kinase assay, and enzyme-linked immunosorbent assay. Incubation with intermediates/ inhibitors of the mevalonate pathway was used to identify the mode of statin action. Statin incubation resulted in a dose-dependent reduction of TLR4 expression (53±7.6% reduction compared with untreated monocytes; P <0.005), transcript levels (68±6.3%; P <0.002), decreased IRAK phosphorylation (37±8.3%; P <0.05), and LPS-induced IL-6, IL-12, tumor necrosis factor (TNF)-α, and B7-1 expression ( P <0.05). Four weeks of treatment with atorvastatin significantly reduced TLR4 expression on circulating CD14 + monocytes by 36.2±4.2% ( P <0.05). Effects of statins were reversed by mevalonate ( P =0.57). Incubation with specific inhibitors of geranylgeranyltransferase (54±4.3%), farnesyltransferase (57±5.1%), or with clostridium-difficile toxin B (58±6.1%, P <0.01) imitated the statin effects. Whereas wortmannin and LY294002 inhibited the statin effect ( P =0.27), incubation with a specific RhoA kinase inhibitor had no effect ( P =0.57). Conclusions— Statins influence TLR4 expression and signaling via inhibition of protein geranylgeranylation and farnesylation. These observations imply interactions with innate immunity as one pleiotropic mechanism.

15 November 2004 in Transplantation
Verified
Journal Article
Closed access
HMHeiko Methe
Heiko Methe
EZEdgar Zimmer
Edgar Zimmer
CGCornelia Grimm
Cornelia Grimm
MNMichael Nabauer
Michael Nabauer
JKJoerg Koglin
Joerg Koglin
Long-term success of cardiac transplantation is limited by various forms of graft rejection. The specific mechanisms initiating and controlling these highly specialized immune processes remain unclear so far. To investigate the role of innate immunity in the development of allograft rejection, we assessed toll-like receptor (TLR)4 expression and typical downstream effects of TLR signaling (B7–1, interleukin [IL]-12, tumor necrosis factor [TNF]-α) in circulating CD14+ monocytes in 38 transplant recipients 1 to 3 years and in 10 transplant recipients 6 to 10 years after transplantation and compared them with 20 healthy controls using reverse transcription polymerase chain reaction, flow cytometry, and enzyme-linked immunoadsorbent assay. The results were matched with endothelial function testing as an early clinical indicator of transplant vasculopathy early after transplantation. Allograft endothelial dysfunction (ED) was defined as a compromised coronary flow reserve (CFVR) to acetylcholine (CFVR<2 in 13 of 38 transplant recipients). In these patients, mRNA transcript levels for TLR4 (P<0.05) and surface expression of TLR4 (P<0.005) and B7–1 (P<0.05) on circulating monocytes as well as secretion of IL-12 (P<0.02) and TNF-α (P<0.05) were significantly higher than in the remaining 25 patients without ED. Compared with the controls, recipients late after transplantation did not show significantly elevated levels of TLR4 or dependent mediators. These results were compared with mRNA levels in a mice model of acute and chronic rejection. Rejecting mice exhibited elevated mRNA levels for mTLR4 and mB7–1. Our results suggest activation of innate immunity in heart-transplant recipients through TLR4 contributes to the development of chronic rejection after cardiac transplantation.

1 May 2007 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
HMHeiko Methe
Heiko Methe
MBMercedes Balcells
Mercedes Balcells
MAMaria del Carmen Alegret
Maria del Carmen Alegret
MSMarina Santacana
Marina Santacana
BMBlanca Molins
Blanca Molins
Elazer R. EdelmanElazer R. Edelman
Elazer R. Edelman
Endothelial cell phenotypes markedly differ, depending upon function and vascular bed of origin. Differences might account for specific susceptibility to pathological conditions. As leukocyte adhesion to activated endothelium is the initiating event in a range of diseases, we compared the influence of vascular bed-specific flow patterns on adhesion molecule expression in human saphenous vein (HSVEC) and coronary artery endothelial cells (HCAEC). In vitro, immune cell attachment was increased 1.6-fold when tumor necrosis factor (TNF)-α-stimulated HSVEC were exposed to coronary artery flow in place of physiological venous flow and 1.9-fold higher compared with attachment to cytokine-stimulated HCAEC exposed to coronary artery flow. This was associated with increased concentrations of soluble E-selectin, VCAM-1, and ICAM-1 in supernatants of HSVEC exposed to coronary artery flow compared with HCAEC exposed to the same flow pattern. Venous and coronary artery flow both increased TNF-α-induced E-selectin and ICAM-1 expression on HSVEC, but only coronary artery flow increased VCAM-1 expression. In marked contrast to HSVEC, venous and coronary artery flow attenuated TNF-α-induced E-selectin and VCAM-1 expression on HCAEC, whereas coronary artery flow further induced ICAM-1 on cytokine-stimulated HCAEC. With the exception of cytokine-induced ICAM-1, adhesion molecule expression on HSVEC exposed to coronary artery flow exceeded expression on HCAEC. Thus ICAM-1 expression involves complex flow-dependent and -independent pathways with marked dissimilarities between the two endothelial cell types studied. Interestingly, Kruppel-like factor (KLF) 4 overexpression in HCAEC and HSVEC significantly reduced TNF-α-induced E-selectin and VCAM-1 expression in static conditions, while ICAM-1 expression remained constant. Furthermore, both flow patterns induced KLF2 and KLF4 expression in HCAEC and HSVEC. Venous and coronary artery flow differentially influence endothelial adhesion molecule and transcription factor expression, depending on the vascular bed of origin. Differences in adhesion molecule expression and subsequent immune cell adhesion between HSVEC and HCAEC may contribute to different susceptibility to pathological conditions.

1 January 2013 in Biomaterials
Verified
Journal Article
Open access
SMSylaja Murikipudi
Sylaja Murikipudi
HMHeiko Methe
Heiko Methe
Elazer R. EdelmanElazer R. Edelman
Elazer R. Edelman
Endothelial cells (EC) are potent bioregulatory cells, modulating thrombosis, inflammation and control over mural smooth muscle cells and vascular health. The biochemical roles of EC are retained when cells are embedded within three-dimensional (3D) denatured collagen matrices. Though substrate mechanics have long been known to affect cellular morphology and function and 3D-EC systems are increasingly used as therapeutic modalities little is known about the effect of substrate mechanics on EC in these 3D systems. In this work, we examined the effect of isolated changes in modulus on EC growth and morphology, extracellular matrix gene expression, modulation of smooth muscle cell growth, and immunogenicity. EC growth, but not morphology was dependent on scaffold modulus. Increased scaffold modulus reduced secretion of smooth muscle cell growth inhibiting heparan sulfate proteoglycans (HSPGs), but had no effect on secreted growth factors, resulting in a loss of smooth muscle cell growth inhibition by EC on high modulus scaffolds. Expression of ICAM-1, VCAM-1 and induction of CD4(+) T cell proliferation was reduced by increased scaffold modulus, and correlated with changes in integrin α5 expression. Expression of several common ECM proteins by EC on stiffer substrates dropped, including collagen IV(α1), collagen IV(α5), fibronectin, HSPGs (perlecan and biglycan). In contrast, expression of elastin and TIMPs were increased. This work shows even modest changes in substrate modulus can have a significant impact on EC function in three-dimensional systems. The mechanism of these changes is not clear, but the data presented here within suggests a model wherein EC attempt to neutralize changes in environmental force balance by altering ECM and integrin expression, leading to changes in effects on downstream signaling and function.